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Abstract
Objective Treatment response assessment in high-grade glio-
mas uses contrast enhanced T1-weighted MRI, but is unreli-
able. Novel advanced MRI techniques have been studied, but
the accuracy is not well known. Therefore, we performed a
systematic meta-analysis to assess the diagnostic accuracy of
anatomical and advanced MRI for treatment response in high-
grade gliomas.
Methods Databases were searched systematically. Study se-
lection and data extraction were done by two authors indepen-
dently. Meta-analysis was performed using a bivariate random
effects model when ≥5 studies were included.
Results AnatomicalMRI (five studies, 166 patients) showed a
pooled sensitivity and specificity of 68% (95%CI 51–81) and
77% (45–93), respectively. Pooled apparent diffusion coeffi-
cients (seven studies, 204 patients) demonstrated a sensitivity
of 71% (60–80) and specificity of 87% (77–93). DSC-
perfusion (18 studies, 708 patients) sensitivity was 87% (82–
91) with a specificity of 86% (77–91). DCE-perfusion (five
studies, 207 patients) sensitivity was 92% (73–98) and
specificity was 85% (76–92). The sensitivity of spectroscopy
(nine studies, 203 patients) was 91% (79–97) and specificity
was 95% (65–99).
Conclusion Advanced techniques showed higher diagnostic
accuracy than anatomical MRI, the highest for spectroscopy,
supporting the use in treatment response assessment in high-
grade gliomas.
Key points
• Treatment response assessment in high-grade gliomas with
anatomical MRI is unreliable
• Novel advanced MRI techniques have been studied, but di-
agnostic accuracy is unknown
• Meta-analysis demonstrates that advanced MRI showed
higher diagnostic accuracy than anatomical MRI
• Highest diagnostic accuracy for spectroscopy and perfusion
MRI
• Supports the incorporation of advanced MRI in high-grade
glioma treatment response assessment
Keywords Glioma . Magnetic resonance imaging .
Meta-analysis . Magnetic resonance spectroscopy .
Treatment response
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Introduction
High-grade gliomas (HGG) are the most common primary
brain tumours in adults and have low survival rates [1].
Current standard therapy consists of surgical gross total or
subtotal resection followed by concomitant chemoradiothera-
py (CCRT) and adjuvant chemotherapy with temozolomide
(TMZ) [2]. Decisions about continuation or discontinuation
of treatment for individual patients with high-grade gliomas
depend on adequate imaging. Similarly, identification of new
active drugs often depends on assessment of an objective re-
sponse rate, which is established by changes in the tumour
seen on imaging [3].
Traditionally, response assessment in HGG is done on the
basis of assessment by contrast (gadolinium) enhanced T1-
weighted MRI. However, this technique represents a disrup-
tion of the blood-brain barrier and thereby does not measure
tumour activity specifically [4]. In many situations, changes in
enhancement do not correlate with response. Up to 50% of the
patients show pseudo-progression, in which an increase in
contrast enhancement does not reflect tumour progression,
but treatment induced changes [5].
To overcome limitations of anatomical T1-weighted MRI
with gadolinium, more advanced imaging techniques have
been employed in patients with HGG [4]. Diffusion-
weightedMRI is frequently performed in routine clinical prac-
tice to image changes in cytoarchitecture and cellular density
[6, 7]. However, even newer imaging methods based on MRI
can identify tumour-induced neovascularization (perfusion
weighted MRI) and changes in concentrations of metabolites
(magnetic resonance spectroscopy) [6–8].
Many small limited studies have shown the potential use-
fulness of the different advanced techniques for assessment of
treatment response in HGG [6–8]. However, a systematic re-
view andmeta-analysis demonstrating the diagnostic accuracy
of the anatomical and all advancedMRI techniques is lacking.
To this end, we conducted a systematic review and meta-
analysis to provide an overview of the diagnostic accuracy of
treatment response assessment in HGG patients. We hypoth-
esized that advanced MRI techniques show a higher diagnos-
tic accuracy compared to anatomical MRI techniques in pa-
tients treated for HHG.
Methods
This systematic review and meta-analysis was performed ac-
cording to the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) criteria [9].
Additionally, the AMSTAR guidelines and the Cochrane
handbook for review of diagnostic test accuracy were also
used [10].
Search strategy
See electronic supplementary material.
Selection criteria
Studies including HGG patients that received first line stan-
dard therapy according to the Stupp protocol and underwent
anatomical or advanced MRI imaging were included [2].
Studies were included if 2x2 tables could be extracted. The
definitive diagnosis, either treatment induced changes or tu-
mour progression, was established by histological follow-up,
imaging follow-up, clinical follow-up, or a combination of
these.
Reasons for exclusion were other intracranial malignan-
cies, metastases, and brainstem or optic gliomas. Studies
among paediatric patients (<18 years) and case reports were
also excluded. Studies that were conducted before 2005 were
excluded as TMZ was not incorporated in standard therapy
before 2005, while TMZ might increase the occurrence of
treatment related imaging changes [7, 11]. Finally, studies that
used a MRI <1.5 Tesla were excluded as this does not repre-
sent current clinical practice.
Study selection, data extraction, and quality assessment
After duplicates were eliminated, studies were screened for
eligibility based on title, abstract, and subsequently on full text
by two authors independently (BD, AH). Data from the in-
cluded studies were extracted with the use of a data extraction
form. Extracted data contained true positives, false positives,
true negatives, false negatives, and general characteristics.
General characteristics included total number of patients,
study design, mean age, and age range of patients, gender,
tumour histology, selection criteria of included patients, refer-
ence standard (histology/imaging/clinical follow-up), MRI
characteristics and time-point of progression on MRI, and
the cut-off value of the index test. If 2x2 tables could not be
generated, the authors were requested to provide these data.
Study quality was assessed according to the quality assess-
ment of diagnostic accuracy studies (QUADAS-2) [12].
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Statistical analysis
Sensitivity and specificity with 95% confidence interval (CI)
were calculated for all MRI modalities in RevMan 5.3
(Cochrane collaboration, Copenhagen, Denmark). Analyses of
study heterogeneity are not recommended, because it is a univar-
iatemeasure that does not account for heterogeneity explained by
phenomena such as positivity threshold effects [13]. Visual in-
spection of the generated forest plots was done to assess hetero-
geneity. We evaluated whether the following factors could ex-
plain heterogeneity; study design, mean age of patients, WHO
type, cut-off value of the index test, type of follow-up, and time
point of progression on MRI (see also Table 1). We performed
subgroup analysis (≥5 studies) to explore and explain heteroge-
neity in test characteristics. Moreover, we evaluated whether out-
liers could be explained by study or patient characteristics, and
we performed sensitivity analysis without outliers to evaluate
how robust the results are.
Bivariate random effects models are used, because hetero-
geneity is to be expected in diagnostic test accuracy studies
[49]. Pooled estimates of sensitivity, specificity, positive like-
lihood ratios, and negative likelihood ratios with 95%CI were
calculated for each index test consisting of five or more stud-
ies, using the MIDAS module for meta-analysis of diagnostic
test accuracy studies in STATA/SE 12.1 (College Station, TX,
USA).
To provide insight in the potential clinical consequences,
we established a hypothetical cohort of 100 HGG patients
suggestive of progression for each MRI technique. We calcu-
lated 2x2 tables by using the mean tumour prevalence of the
reference standard, pooled sensitivities and specificities of
each MRI modality, and we present the number of misclassi-
fications, false positives and false negatives. The hypothetical
tumour prevalence was based on the mean tumour prevalence
of the cohort studies included in this meta-analysis.
Results
A total of 1371 unduplicated studies were identified through
our electronic database search (Fig. 1). After selection based
on title and abstract, the remaining studies underwent full-text
eligibility assessment. Full text assessment resulted in the
identification of 45 relevant studies [14–48, 50–59]. We re-
quested data to generate 2x2 tables from ten studies, but none
of the authors could provide the requested data, resulting in no
unpublished data in this meta-analysis. Thus, final inclusion
consisted of a total of 35 studies in this systematic review of
which four (11%) were abstracts only [25, 26, 37, 38]. The
study characteristics of the included and excluded studies are
shown in Table 1 and Table 2, respectively.
The included studies consisted of 1174 patients with a
mean age of 51.6 years of whom 61.3% were male
(Table 3). The initial lesion was proven to be WHO type III
in 11% (N = 124) and WHO type IV in 81% (N = 951). The
remaining 8% (N = 99) was unspecified HGG. Mean tumour
prevalence of the 34 cohort studies was 60% (range 31–85%).
One case-control study was not taken into account for the
calculation of the tumour prevalence [42]. Histological
follow-up was used in 43% of patients (N = 502), imaging
follow-up in 35% of patients (N = 406), clinical follow-up in
<1% of patients (N = 3), and a combination of follow-up
methods was used in 22% of patients (N = 263).
Several of the included studies analysed multiple MRI mo-
dalities; therefore, a total of five anatomical MRI studies
(N = 166) [23, 29, 39, 44, 47], seven apparent diffusion coef-
ficient (ADC) studies (N = 204) [14, 15, 24, 25, 30, 33, 41], 18
dynamic susceptibility contrast (DSC) studies (N = 708)
[15–17, 19, 20, 22–28, 30, 31, 37, 38, 40, 45], five studies
on dynamic contrast enhanced (DCE) (N = 207) [18, 21, 32,
40, 42], two arterial spin labelling (ASL) studies (N = 102)
[20, 40], and nine magnetic resonance spectroscopy (MRS)
studies (N = 203) were included [22, 24, 34–36, 40, 43, 46,
48].
Methodological quality of included studies
See electronic supplementary material and Fig. 2.
Main findings
The forest plots and pooled results are demonstrated in Fig. 3
and Table 4, respectively. The anatomical MRI forest plot
(five studies, 166 patients) shows a high variation in both
sensitivity and specificity, with wide confidence intervals for
three studies [23, 29, 44]. The wide confidence intervals of
two references could be explained by the small sample size
[23, 29]. The moderate methodological quality might explain
the wider confidence intervals in the other study [44].
Anatomical MRI showed a pooled sensitivity and specificity
of 68% (95%CI 51–81) and 77% (95%CI 45–93),
respectively.
Sensitivity and specificity were both homogeneous in the
forest plot of the ADC (seven studies, 204 patients); however,
the confidence intervals are rather wide for the specificity. For
ADC pooled sensitivity and specificity were 71% (95%CI 60–
80), and 87% (95%CI 77–93), respectively. One abstract was
included in this group [25], but sensitivity analysis excluding
this study showed comparable sensitivity (75%, 95%CI 65–
83) and specificity (85%, 95%CI 72–93) [15].
The sensitivity of the DSC (18 studies, 708 patients) is
homogeneous with small confidence intervals. The specificity
showed slightly more variability with wider confidence inter-
vals. DSC showed a sensitivity of 87% (95%CI 82–91) and
specificity of 86% (95%CI 77–91). This group included four
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studies showed minor increase in of the sensitivity with 87%
(95%CI 81–92) and specificity of 89% (95%CI 80–95).
The confidence interval of the specificity of one study for
the DCE (five studies, 207 patients) was also wide without
clear reason [32], but the other studies showed small confi-
dence intervals in both the sensitivity and specificity. For DCE
the pooled sensitivity was slightly higher compared to the
DSC with a sensitivity and specificity of 92% (95%CI 73–
98) and 85% (95%CI 76–92), respectively.
For ASL, too few studies (two studies, 102 patients) were
included in the meta-analysis for pooled accuracy estimate
calculation. ASL showed a sensitivity range of 52–79% and
a specificity range of 64–82%.
The forest plot of the MRS (nine studies, 203 patients) was
overall homogeneous and showed small confidence intervals,
with one exception in the specificity, possibly due to a mod-
erate methodological quality as blinding was not assured both
for the interpretation of the MRI as well as the reference stan-
dard [36]. MRS showed the highest pooled sensitivity and
specificity with 91% (95%CI 79–97) and 95% (95%CI 65–
99), respectively. Sensitivity analysis with the exclusion of
one study [36] showed that it has only minor influences on
the results altering the group sensitivity and specificity to 92%
(95%CI 78–97) and 96 (95%CI 74–100).
Study design, mean age of patients, WHO type, cut-off
value of the index test, type of follow-up, and time point of
progression on MRI (see also Table 1) were evaluated as co-
variates and showed to be unable to explain differences in
sensitivity and specificity of the studies.
To provide insight in the clinical implication of the inves-
tigated MRI techniques we also calculated the missed number
of patients with true progression and total number of misclas-
sifications in a hypothetical cohort of 100 HGG patients. We
used the found tumour prevalence (60%) in this current anal-
ysis and the pooled sensitivity and specificity of each MRI
technique. With anatomical MRI 19 recurrent tumours would
be missed. For ADC and DSC this would be 17 and eight
missed tumours, respectively. Both DCE and MRS would
result in the least missed cases of progression (N = 5).
Anatomical MRI would show a total of 28 misclassified pa-
tients. This would be 22, 14, and 11 for ADC, DSC, and DCE,
respectively. MRS would induce the lowest number of mis-
classifications, with a total of seven out of the 100 patients
being misclassified.
Discussion
This meta-analysis including 35 studies, is the first pooling the
results of all diagnostic MRI techniques in HGG patients fol-
lowing treatment. We demonstrated that all advanced MRI
techniques showed a higher diagnostic accuracy than anatom-
ical MRI in the differentiation between treatment induced
changes and true progression. Among the advancedMRI tech-
niques, MRS showed the highest diagnostic accuracy follow-
ed by perfusion MRI.
Diffusion derived ADC values showed the lowest accuracy
of all advanced MRI techniques; however, it is currently most
commonly available. We showed that the employment of nov-
el advanced MRI techniques had higher diagnostic accuracy
in the differentiation between true progression and treatment
induced changes. Therefore, we suggest the incorporation of
other advanced MRI in treatment assessment in HGG on top
of DWI. This is supported by several studies that showed that
diagnostic accuracy could significantly be enhanced by a
combination of two or more advanced MRI techniques
[60, 61]. Most important, adding MRS to perfusion weighted
techniques could increase the diagnostic accuracy up to 90%
in one study [40].
1816 studies identified through 
database searching 
338 from PubMed 
763 from EMBASE 
715 from Web of Science
1371 studies after duplicates 
removed
863 studies excluded based on 
title
508 abstracts of studies screened
402 studies excluded based on 
abstract
61 studies excluded 
31 different patient populations 
18 no standard treatment 
7   no (adequate) MRI data 
5   no treatment response       
     assessment
106 full-text studies assessed for 
eligibility 
45 studies included in qualitative 
synthesis
10 studies excluded as no 2x2 
table was possible 
35 studies included in quantitative 
synthesis  
  5 anatomical MRI
  7 ADC 
18 DSC 
  5 DCE 
  2 ASL 
  9 MRS
Fig. 1 Flow chart of included studies. Flow chart of included studies.
Abbreviations: ADC = apparent diffusion coefficient; ASL = arterial spin
labelling; DCE = dynamic contrast enhanced; DSC = dynamic
susceptibility contrast; MRI = magnetic resonance imaging;










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































With a pooled sensitivity and specificity of 91% and
95%, respectively, we found MRS to be the most prom-
ising advanced MRI technique for the treatment re-
sponse assessment in HGG. MRS, however, has several
limitations. First, the voxel sizes are relatively large
possibly leading to partial volume effects between recur-
rent tumour and treatment induced changes [4].
Detection of smaller lesions on MRS is, therefore, chal-
lenging. Secondly, due to low metabolite concentrations,
a considerable number of acquisitions are required,
resulting in long scan times [7]. Finally, MRS is tech-
nically challenging because of the need to exclude sig-
nal contamination from tissues adjacent to the tumour,
such as lipids (from the scalp) and water (from the
ventricles). Surgical clips also disrupt the local field
homogeneity and may affect the quality of the data.
These limitations challenge the incorporation of MRS
in daily practice; however, a multivoxel technique
should be feasible to perform in most clinics.
Various metabolic ratios were used in the MRS stud-
ies. In this meta-analysis we were unable to differentiate
between the various metabolite ratios in MRS, because
of the variability of the included ratios. Moreover, three
of the included studies did not specify the investigated
metabolite ratio [35, 43, 46]. However, five out of the
nine included studies identified choline/creatine ratio as
the best predictor in the differentiation between
true progression and treatment induced changes [22,
24, 40, 43, 48]. One study reported similar results for
choline/creatine and lactate/choline ratios, with the latter
showing a slightly higher accuracy [34]. Furthermore,
the included studies used various thresholds, or did
not specify the used thresholds. Only one study used a
considerably low cut-off value of 1.07, possibly




































































































































































































































































































































































































































































































































Table 3 General characteristics of included patients
Patients (N) 1174
Mean age (years) 51.6
% Male 61.3
Histology
- WHO III 124
- WHO IV 951






General characteristics are shown for the total of all included patients. See
Table 1 for abbreviations.
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Among the perfusion techniques, DSC is the most
widely used method. However, DSC is a dynamic
parameter and values can vary over time. Yet, there is
no consensus about the opt imum t ime poin t .
Furthermore, steroids are known to influence DSC mea-
sures, which are regularly prescribed if clinical deterio-
ration due to true progression or treatment effects is
present. Finally, there is no automatic post-processing
method for identifying regions of interest, and is thus
highly operator dependant [4]. This operator-dependant
variability is also displayed in our meta-analysis by the
different rCBV thresholds among studies (range 0.71–
3.7).
DCE showed highest diagnostic accuracy among the
perfusion techniques in the differentiation between treat-
ment induced changes and true progression in this meta-
analysis. At present, DCE is not widely used in a clin-
ical setting primarily due to complicated quantification
of the DCE parameters. Although DCE MRI has limited
temporal resolution, the spatial resolution is higher than
DSC MRI. This makes DCE more accurate in mixed
lesions showing both true progression and treatment in-
duced changes [7].
Although ASL is a complete non-invasive and quan-
titative method, the universal availability remains its
largest limitation [8]. We could only identify two ASL
studies and, therefore, it is not possible to make judg-
ments reliably on the diagnostic accuracy of ASL in
differentiating between true progression and treatment
induced changes.
In our hypothetical cohort of 100 patients, ADC showed
fewer misclassifications than anatomical MRI and could thus
provide guidance to the definite diagnosis. ADC is a quanti-
fiable measurement and can be achieved fast and easily [4].
However, the reliability of ADC can be affected by oedema
and the formation of fibrosis in treatment induced changes [6].
A limitation that also should be noted is the inclusion of
four abstracts. Inclusion of abstracts prevent a publication bi-
as. However, quality and extend of information provided in
abstracts is limited and they have not undergone the full peer
review process as full articles.
Another possible limitation is that not all studies ap-
plied the same reference test. However, either histology
or imaging follow-up was performed in all except three
patients to provide definite diagnosis. Although we con-
sidered both histological follow-up and imaging follow-
up to be reliable diagnostic methods, the reliability may
not be equivalent . According to the Response
Assessment in Neuro-Oncology (RANO) criteria, the de-
velopment of pseudo-progression is limited to the first
3 months after CCRT [3]. However, it is suggested that
30% of pseudo-progression cases occur after more than
three months post-CCRT [62]. Therefore, the accuracy
of the reference test could differ between the included
studies depending on the follow-up duration. However,
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Fig. 2 Quality assessment of included studies. The risk of bias in four
different domains and concerns about applicability are shown for the
included studies. High risk ( ), unclear risk ( ) and low risk ( )
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no difference could be seen between early follow-up
studies and studies that were conducted more than three
months after CCRT.
Largemulticentre longitudinal prospective trials are needed
to define the optimum time for assessment of metabolic and
physiological MRI parameters using advanced techniques.
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Fig. 3 Forest plots with diagnostic accuracy of different MRI techniques. Diagnostic accuracy and the 2x2 table are displayed with true positives (TP),
false positives (FP), false negatives (FN) and true negative (TN). Sensitivity and specificity with the 95% Confidence intervals (CI) are given
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These should be in relation to histopathological changes
in HGG, treatment effects, and patient outcomes. This
would allow for testing all techniques in the same pop-
ulation, which would overcome one major limitation of
the current meta-analysis with indirect comparisons only
as a direct comparison between tests in a meta-analysis
can only be performed if both contain >10 studies.
These new prospective trials should use standardised
cut-off values also, although they might remain arbitrary
because of the heterogeneity in the biological activity of
HGG and the use of different MRI systems. An advice
with the best cut-off values and ratios for the anatomi-
cal and advance MRI sequences most precisely defining
post therapy changes from tumour progression is cur-
rently hindered by the high variability of the used cut-
offs and variables. However, it would be a valuable
guideline for the clinician in daily practise. The latter
could be addressed using normalised cut-off values.
Despite these possible limitations, implication into clin-
ical practice would be an important step in making an
accurate treatment decisions for HGG patients.
Conclusion
Our meta-analysis demonstrated a clear advantage of
advanced MRI techniques for differentiation between
true progression and treatment-induced changes in pa-
tients with HGG. All advanced MRI techniques showed
a higher diagnostic accuracy than anatomical MRI.
MRS showed the highest diagnostic accuracy followed
by perfusion. Although a diffusion technique with ADC
values is currently the most common used advanced
technique, it showed the lowest diagnostic accuracy of
all advanced MRI techniques. This study supports the
extension of other advanced MRI techniques for assess-
ment of treatment response in patients with HGG.
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